Research.Patient.info
Stargardt Disease (STGD1) research hub
2 indexed studies · 0 currently recruiting
- authorisedTherapeutic confirmatory (Phase III)
A Phase 3 Multicenter, Double-Masked, Randomized, Placebo-Controlled Study to Investigate the Safety, Tolerability, and Efficacy of Gildeuretinol Acetate (ALK-001) on the Progression of Stargardt Disease (STGD) - NORTHSTAR
This phase 3 study tests whether a new medicine called gildeuretinol acetate can slow down vision loss in adults with Stargardt disease. Participants take daily capsules containing either the trial drug or an inactive dummy pill (placebo) for two years, while eye doctors track their vision and retinal health.
Belgium · France · Spain - authorisedPhase I and Phase II (Integrated)- First administration to humans
An Open-label, Multicenter, Two Part, Ascending Dose Followed by a Controlled Trial to Assess the Safety and Efficacy of a Subretinal Administration of AAVB-039 in Participants with Stargardt Disease (STGD1) (CELESTE)
This study is testing a new treatment, AAVB-039, for Stargardt disease. It's the first time this treatment is being given to people. Researchers want to see if it's safe and if it helps improve vision or slow down the disease.
Belgium · Italy · Netherlands